SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

Lung cancer is the most common cancer worldwide as well as the leading cause of cancer related deaths as reported by Torre et al (CA Cancer J Clin 65:87–108, 2015]. Non-small cell lung cancer (NSCLC) accounts for up to 85 % of all lung cancers. Multiple advances in the staging, diagnostic procedures, therapeutic options, as well as molecular knowledge have been achieved during the past years, although the overall outlook has not greatly changed for the majority of patients with the overall 5-year survival having marginally increased over the last decade from 15.7 to 17.4 % as reported by Howlader et al.  (SEER Cancer Statistics Review 2015).

• Publication year

  2015

• Venue

  Clinical and Translational Oncology

• Publication date

  2015-12-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12094-015-1455-zPMID 26691657PMCID 4689744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

  2015cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

  2015cited by this paper
• Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

  2015cited by this paper
• Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

  2015cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.

  2014cited by this paper
• Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

  2014cited by this paper
• An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.

  2014cited by this paper
• First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

  2014cited by this paper
• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

  2013cited by this paper
• Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.

  2013cited by this paper
• PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

  2013cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

  2013cited by this paper
• Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.

  2013cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013influential reference
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214.

  2011cited by this paper
• [Postoperative radiotherapy in non-small cell lung cancer].

  2011cited by this paper
• Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small cell lung cancer: a phase III randomized controlled trial

  2010cited by this paper
• Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

  2010cited by this paper
• Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

  2010cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.

  2009cited by this paper
• Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.

  2009cited by this paper
• The revised TNM staging system for lung cancer.

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

  2009cited by this paper
• Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

  2008cited by this paper
• Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

  2008cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008cited by this paper
• Chemotherapy and surgery versus surgery alone in non-small cell lung cancer.

  2007cited by this paper
• Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

  2007cited by this paper
• Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis.

  2006cited by this paper
• SEER Cancer Statistics Review, 1975-2003

  2006cited by this paper
• Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.

  2005cited by this paper
• Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

  2000cited by this paper
• Chemotherapy plus Radiotherapy Compared with Radiotherapy Alone in the Treatment of Locally Advanced, Unresectable, Non-Small-Cell Lung Cancer

  1996cited by this paper
• Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

  1995cited by this paper

• THE LIPOXYGENASE INHIBITOR ML351 AFFECTS CELL VIABILITY BY REGULATING AUTOPHAGY AND SEMAPHORIN SIGNALING PATHWAYS IN A549 CELLS

  2026cites this paper
• Genome-wide association, single-cell, and spatial transcriptomics analyses reveal the role of the STK24-expressing positive cells in LUAD progression and the tumor microenvironment, identifying STK24 as a potential therapeutic target

  2025cites this paper
• Disruption of epidermal growth factor receptor signaling and cytoskeletal dynamics by mebendazole and gefitinib synergistically impairs paracrine cytokine signaling in non-small cell lung cancer and triple-negative breast cancer Cell lines

  2025cites this paper
• NAT10-mediated lipid metabolic reprogramming drives EGFR-TKI resistance in non-small cell lung cancer via ac4C-dependent mRNA stabilization

  2025cites this paper
• Dosimetric Predictors of Acute Radiation Pneumonitis and Esophagitis in Hypofractionated Thoracic Irradiation of Non-Small Cell Lung Cancer Patients With Poor Prognostic Factors

  2024cites this paper
• Cost-effectiveness of a machine learning risk prediction model (LungFlag) in the selection of high-risk individuals for non-small cell lung cancer screening in Spain

  2024cites this paper
• Synergistic anticancer activity of resveratrol with cisplatin and carboplatin in A549 lung adenocarcinoma cells.

  2024cites this paper
• A lung cancer diagnosis and treatment dataset with geno- and phenotypical characteristics of the patient

  2024cites this paper
• Recent advances in non-small cell lung cancer targeted therapy; an update review

  2023influential citation
• Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool

  2023cites this paper
• Green tea-derived theabrownin suppresses human non-small cell lung carcinoma in xenograft model through activation of not only p53 signaling but also MAPK/JNK signaling pathway.

  2022cites this paper
• Antiproliferative and Proapoptotic Effects of Phenanthrene Derivatives Isolated from Bletilla striata on A549 Lung Cancer Cells

  2022cites this paper
• Differences in Quality of Life and Emotional Well-being in Breast, Colon, and Lung Cancer Patients During Outpatient Adjuvant Chemotherapy

  2022cites this paper
• Upregulation of Serum miR-629 Predicts Poor Prognosis for Non-Small-Cell Lung Cancer

  2021cites this paper
• Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment.

  2021cites this paper
• Sequential Pneumonitis with Ground-glass Opacity during Durvalumab Therapy after Chemoradiation for Stage III Non-Small Cell Lung Cancer

  2021cites this paper
• Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients

  2021cites this paper
• Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells.

  2020cites this paper
• Bioremediation of Wastewater – Effect of Algae in Bioremediation of Nitrate and Phosphate Content in Wastewater

  2020cites this paper
• Precision Medicine in Lung Cancer: Challenges and Opportunities in Diagnostic and Therapeutic Purposes

  2020cites this paper
• Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer

  2020cites this paper
• Curcumin potentiates the galbanic acid-induced anti-tumor effect in non-small cell lung cancer cells through inhibiting Akt/mTOR signaling pathway.

  2019cites this paper
• MiRNA-195-5p Functions as a Tumor Suppressor and a Predictive of Poor Prognosis in Non-small Cell Lung Cancer by Directly Targeting CIAPIN1

  2019cites this paper
• Demethoxycurcumin sensitizes the response of non-small cell lung cancer to cisplatin through downregulation of TP and ERCC1-related pathways.

  2019cites this paper
• Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial

  2019cites this paper
• 18FDG PET/CT & arterial inflammation: predicting cardiovascular events in lung cancer.

  2019cites this paper
• Treatment outcome of patients with unresectable stage III non-small cell lung cancer and interstitial pneumonia.

  2019cites this paper
• Targeted therapy combined with thoracic radiotherapy for non-small cell lung cancer

  2019cites this paper
• Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective

  2019cites this paper
• The value of human epididymis protein 4 (HE4) as a serum tumor marker for accurate bone metastases finding by whole-body bone scintigraphy in lung cancer patients.

  2019cites this paper
• COPD and lung cancer: underdiagnosis and clinical characterization

  2019cites this paper
• Intraoperative oxygen challenge for toleration of single lung ventilation in a patient with severe obstructive airway disease: A case report

  2019cites this paper
• Long Non-coding RNA LOC285194 in Cancer.

  2019cites this paper
• Beneficios de la fisioterapia respiratoria preoperatoria en pacientes por cáncer de pulmón

  2019cites this paper
• Expression characteristics of AXL and YAP in non-small cell lung cancer and prognostic importance.

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

  2018cites this paper
• The Relationship Between Guideline-Recommended Initiation of Therapy, Outcomes, and Cost for Patients with Metastatic Non-Small Cell Lung Cancer

  2018cites this paper
• Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum

  2018cites this paper
• Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS

  2018cites this paper
• Licarin A induces cell death by activation of autophagy and apoptosis in non-small cell lung cancer cells

  2018cites this paper
• Left sleeve lobectomy versus left pneumonectomy for the management of patients with non‐small cell lung cancer

  2018cites this paper
• Guía SEOM-SERAM-SEMNIM sobre el empleo de las técnicas de imagen funcional y molecular en el cáncer de pulmón no microcítico avanzado

  2018cites this paper
• Expression of immune checkpoints genes in tumour samples from resectable NSCLC patients. Role as prognostic biomarkers.

  2017cites this paper
• Pemetrexed en cáncer de pulmón no microcítico en estadíos avanzado o metastásico: efectividad, seguridad y perfil de utilización en hospitales del sistema sanitario público de Andalucía

  2017cites this paper
• Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer

  2017cites this paper
• Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis.

  2017cites this paper
• The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer

  2017cites this paper
• From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?

  2017cites this paper
• SEOM–SERAM–SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer

  2017cites this paper
• Prognostic Factors in Non-Small Cell Lung Cancer (NSCLC)

  2017cites this paper
• Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model

  2017cites this paper
• Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer

  2017cites this paper
• Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer.

  2017influential citation
• Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

  2016cites this paper
• Side population cells from long-term passage non-small cell lung cancer cells display loss of cancer stem cell-like properties and chemoradioresistance.

  2016cites this paper
• Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients

  2016cites this paper
• Video-assisted thoracoscopic lobectomy versus open lobectomy for clinical stage I non small cell lung cancer : a case-control study

  2016cites this paper
• Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials

  2016cites this paper
• Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

  2015cites this paper
• SEOM Guidelines 2015: a new era in the collaboration with the Spanish Cancer Research Cooperative Groups

  2015cites this paper
• Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

  2015cites this paper
• Adjuvant chemotherapy in non-small cell lung cancer: state-of- the-art

  2015cites this paper
• Clinicoeconomics and Outcomes Research Dovepress Costs of Adverse Events Associated with Erlotinib or Afatinib in First-line Treatment of Advanced Egfr-positive Non-small Cell Lung Cancer

  year unknowncites this paper